# Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

> **NCT00299182** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** AMG 531
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Dexamethasone
- **DRUG:** Methotrexate
- **DRUG:** Cytarabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00299182
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299182, "Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00299182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*